Arcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $21.00 at Citigroup

Arcturus Therapeutics (NASDAQ:ARCT) had its price objective cut by stock analysts at Citigroup from $66.00 to $21.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Citigroup’s price target would suggest a potential upside of 189.66% from the company’s previous close.

ARCT has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. Piper Sandler decreased their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday. Wall Street Zen cut shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. HC Wainwright reduced their price target on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Finally, Roth Mkm initiated coverage on Arcturus Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Arcturus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

Arcturus Therapeutics Trading Down 4.4%

Arcturus Therapeutics stock traded down $0.33 on Thursday, hitting $7.25. 473,351 shares of the stock traded hands, compared to its average volume of 474,978. Arcturus Therapeutics has a 1 year low of $5.85 and a 1 year high of $24.17. The firm has a market cap of $205.97 million, a P/E ratio of -3.05 and a beta of 2.40. The business’s fifty day simple moving average is $7.29 and its 200 day simple moving average is $11.35.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.11). Arcturus Therapeutics had a negative return on equity of 28.63% and a negative net margin of 80.19%.The business had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $14.32 million. As a group, analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. Osaic Holdings Inc. grew its position in shares of Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 2,586 shares during the last quarter. Compagnie Lombard Odier SCmA purchased a new stake in shares of Arcturus Therapeutics during the 3rd quarter worth approximately $111,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 27.5% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,567 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Arcturus Therapeutics by 42.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 2,313 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Arcturus Therapeutics

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Company plans to launch a 12‑week Phase II trial in cystic fibrosis and expects regulatory clarity for ARCT‑810 in 2026 — a clear clinical catalyst that could re‑rate the stock if data or guidance is favorable. Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
• Positive Sentiment: Management will appear at the Leerink Partners 2026 Global Healthcare Conference (fireside chat on Mar 11), increasing investor access and visibility ahead of upcoming developmental and regulatory milestones. Arcturus Therapeutics to Attend Upcoming Investor Conference
• Neutral Sentiment: Citigroup raised its price target from $7 to $8 and maintained a neutral rating — a modest positive to sentiment but not a strong upgrade. Citigroup raises price target
• Neutral Sentiment: Reported short‑interest data in recent feeds appears inconsistent/zero and likely reflects reporting noise rather than a clear short‑squeeze signal; treat these figures cautiously. (Data item compiled from market feeds.)
• Negative Sentiment: Q4 results disappointed: GAAP loss per share of $1.03 missed consensus (~$0.92) and revenue of ~$7.2M fell well short of estimates (~$14.3M), pressuring near‑term sentiment and valuation expectations. Arcturus Q4 press release / financials
• Negative Sentiment: Piper Sandler sharply reduced its price target from $72 to $25 (still “overweight”), which lowers long‑term street expectations and may increase short‑term selling pressure despite the maintained rating. Piper Sandler lowers price target
• Negative Sentiment: Market coverage highlighted the weak quarter as the reason for a sell‑off in early March; revenue shortfall and a wider loss raise funding and runway questions until clinical progress materializes. Arcturus falls on weak quarterly revenue

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.